{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:27:17Z","timestamp":1792686437746,"version":"4.5.0"},"reference-count":34,"publisher":"BMJ","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Reports"],"accepted":{"date-parts":[[2017,10,22]]},"abstract":"<jats:p>We report a patient with chronic lymphocytic leukaemia (CLL) who was treated with idelalisib, a PI3K\u03b4 inhibitor with rituximab. After 20 weeks of treatment, the patient developed classical signs and symptoms of polymyalgia rheumatica (PMR) in association with an elevated C reactive protein of 74\u2009mg\/L. After 2\u2009weeks of prednisolone 15\u2009mg daily symptoms had resolved and acute phase markers normalised. To our knowledge, this is the first report of PMR developing as a complication of PI3K\u03b4 inhibitor treatment of CLL.<\/jats:p>","DOI":"10.1136\/bcr-2017-221065","type":"journal-article","created":{"date-parts":[[2017,11,9]],"date-time":"2017-11-09T06:45:25Z","timestamp":1510209925000},"page":"bcr-2017-221065","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Polymyalgia rheumatica development in a patient under PI3K inhibitor therapy for chronic lymphocytic leukaemia"],"prefix":"10.1136","volume":"2017","author":[{"given":"Sanah","family":"Sajawal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah L","family":"Mackie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Hillmen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"McGonagle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2017,11,8]]},"reference":[{"key":"2025042713015925000_2017.nov08_1.bcr-2017-221065.1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f6937"},{"key":"2025042713015925000_2017.nov08_1.bcr-2017-221065.2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207492"},{"key":"2025042713015925000_2017.nov08_1.bcr-2017-221065.3","first-page":"2179","article-title":"The spectrum of conditions mimicking polymyalgia rheumatica in Northwestern Spain","volume":"27","author":"Gonzalez-Gay","year":"2000","journal-title":"J Rheumatol"},{"key":"2025042713015925000_2017.nov08_1.bcr-2017-221065.4","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2034"},{"key":"2025042713015925000_2017.nov08_1.bcr-2017-221065.5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-535047"},{"key":"2025042713015925000_2017.nov08_1.bcr-2017-221065.6","doi-asserted-by":"publisher","DOI":"10.1177\/1060028015594813"},{"key":"2025042713015925000_2017.nov08_1.bcr-2017-221065.7","unstructured":"National Institute For Health And Care Excellence. Idelalisib for treating chronic lymphocytic leukaemia. London: NICE, 2016. https:\/\/www.nice.org.uk\/guidance\/ta359\/resources\/idelalisib-for-treating-chronic-lymphocytic-leukaemia-82602676706245 (accessed 26 Oct 2016)."},{"key":"2025042713015925000_2017.nov08_1.bcr-2017-221065.8","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1073\/pnas.83.1.130","article-title":"The gene for human p53 cellular tumor antigen is located on chromosome 17 short arm (17p13)","volume":"83","author":"McBride","year":"1986","journal-title":"Proc Nat Aca Sci"},{"key":"2025042713015925000_2017.nov08_1.bcr-2017-221065.9","doi-asserted-by":"crossref","first-page":"233","DOI":"10.20524\/aog.2016.0022","article-title":"Idelalisib: a rare cause of enterocolitis","volume":"29","author":"Balagoni","year":"2016","journal-title":"Ann Gastroenterol"},{"key":"2025042713015925000_2017.nov08_1.bcr-2017-221065.10","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000000522"},{"key":"2025042713015925000_2017.nov08_1.bcr-2017-221065.11","unstructured":"Zydelig. Full prescribing information. Foster City, CA: Gilead Sciences Inc, 2014. http:\/\/www.gilead.com\/~\/media\/Files\/pdfs\/medicines\/oncology\/zydelig\/zydelig_pi.pdf (accessed 26 Oct 2016)."},{"key":"2025042713015925000_2017.nov08_1.bcr-2017-221065.12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-707133"},{"key":"2025042713015925000_2017.nov08_1.bcr-2017-221065.13","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.036533"},{"key":"2025042713015925000_2017.nov08_1.bcr-2017-221065.14","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1002\/art.38625","article-title":"Disturbed B cell homeostasis in newly diagnosed giant cell arteritis and polymyalgia rheumatica","volume":"66","author":"van der Geest","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2025042713015925000_2017.nov08_1.bcr-2017-221065.15","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3109\/03009747709095438","article-title":"Polymyalgia rheumatica and chronic lymphatic leukaemia","volume":"6","author":"von Knorring","year":"1977","journal-title":"Scand J Rheumatol"},{"key":"2025042713015925000_2017.nov08_1.bcr-2017-221065.16","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/39.4.417"},{"key":"2025042713015925000_2017.nov08_1.bcr-2017-221065.17","doi-asserted-by":"publisher","DOI":"10.1007\/s100670200081"},{"key":"2025042713015925000_2017.nov08_1.bcr-2017-221065.18","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203465"},{"key":"2025042713015925000_2017.nov08_1.bcr-2017-221065.19","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kev360"},{"key":"2025042713015925000_2017.nov08_1.bcr-2017-221065.20","first-page":"115","article-title":"Polymyalgia rheumatica in a renal transplant patient","volume":"105","author":"Banerjee","year":"2008","journal-title":"J Ark Med Soc"},{"key":"2025042713015925000_2017.nov08_1.bcr-2017-221065.21","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1002\/art.38282","article-title":"Drug-associated polymyalgia rheumatica\/giant cell arteritis occurring in two patients after treatment with ipilimumab, an antagonist of ctla-4","volume":"66","author":"Goldstein","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2025042713015925000_2017.nov08_1.bcr-2017-221065.22","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/art.40044","article-title":"A Randomized, Double-Blind Trial of Abatacept (CTLA-4Ig) for the Treatment of Giant Cell Arteritis","volume":"69","author":"Langford","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2025042713015925000_2017.nov08_1.bcr-2017-221065.23","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.4161\/cc.6444","article-title":"Directing T cell differentiation and function with small molecule inhibitors","volume":"7","author":"Bruno","year":"2008","journal-title":"Cell Cycle"},{"key":"2025042713015925000_2017.nov08_1.bcr-2017-221065.24","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3389\/fimmu.2012.00244","article-title":"Does the PI3K pathway promote or antagonize regulatory T cell development and function?","volume":"3","author":"Soond","year":"2012","journal-title":"Front Immunol"},{"key":"2025042713015925000_2017.nov08_1.bcr-2017-221065.25","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-14-0095"},{"key":"2025042713015925000_2017.nov08_1.bcr-2017-221065.26","doi-asserted-by":"crossref","first-page":"231","DOI":"10.3389\/fimmu.2013.00231","article-title":"The impact of aging on regulatory T-cells","volume":"4","author":"Fessler","year":"2013","journal-title":"Front Immunol"},{"key":"2025042713015925000_2017.nov08_1.bcr-2017-221065.27","first-page":"640.12","article-title":"AB0052\u2005Polymyalgia rheumatica is characterized by pro-inflammatory, senescent CD8+ T cells","volume":"71","author":"van der Geest","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2025042713015925000_2017.nov08_1.bcr-2017-221065.28","doi-asserted-by":"publisher","DOI":"10.1002\/art.34647"},{"key":"2025042713015925000_2017.nov08_1.bcr-2017-221065.29","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211216"},{"key":"2025042713015925000_2017.nov08_1.bcr-2017-221065.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2015.11.016"},{"key":"2025042713015925000_2017.nov08_1.bcr-2017-221065.31","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0915174107"},{"key":"2025042713015925000_2017.nov08_1.bcr-2017-221065.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2013.01.003"},{"key":"2025042713015925000_2017.nov08_1.bcr-2017-221065.33","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1002\/art.39740","article-title":"Brief Report: A Prospective Open-Label Phase IIa Trial of Tocilizumab in the Treatment of Polymyalgia Rheumatica","volume":"68","author":"Lally","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2025042713015925000_2017.nov08_1.bcr-2017-221065.34","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210070"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2017-221065","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,27]],"date-time":"2025-04-27T20:02:10Z","timestamp":1745784130000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2017-221065"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,8]]},"references-count":34,"alternative-id":["10.1136\/bcr-2017-221065"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2017-221065","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,8]]}}}